6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
safety	NN	safety	safety	safeti	N	O
concerns	NNS	concerns	concern	concern	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

New	NNP	new	new	new	N	B-AdverseReaction
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
Injury	NNP	injury	injury	injuri	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
with	IN	with	with	with	N	O
potassium	NN	potassium	potassium	potassium	Y	O
-	:	-	-	-	N	O
depleting	NN	depleting	depleting	deplet	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O

SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
sanofi	SYM	sanofi	sanofi	sanofi	N	O
-	:	-	-	-	N	O
aventis	NN	aventis	aventis	aventi	N	O
U.S.	NNP	u.s.	u.s.	u.s.	N	O

LLC	NNP	llc	llc	llc	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
633	CD	633	633	633	N	O
-	:	-	-	-	N	O
1610	CD	1610	1610	1610	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
evaluation	NN	evaluation	evaluation	evalu	N	O
of	IN	of	of	of	N	O
dronedarone	NN	dronedarone	dronedarone	dronedaron	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
AF	NNP	af	af	af	N	O
or	CC	or	or	or	N	O
AFL	NNP	afl	afl	afl	N	O
is	VBZ	is	is	is	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
5	CD	5	5	5	N	O
placebo	NN	placebo	placebo	placebo	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
ATHENA	NNP	athena	athena	athena	N	O
,	,	,	,	,	N	O
EURIDIS	NNP	euridis	euridis	euridi	N	O
,	,	,	,	,	N	O
ADONIS	NNP	adonis	adonis	adoni	N	O
,	,	,	,	,	N	O
ERATO	NNP	erato	erato	erato	N	O
and	CC	and	and	and	N	O
DAFNE	NNP	dafne	dafne	dafn	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
6285	CD	6285	6285	6285	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
and	CC	and	and	and	N	O
treated	VBN	treated	treated	treat	N	O
,	,	,	,	,	N	O
3282	CD	3282	3282	3282	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2875	CD	2875	2875	2875	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	NN	mean	mean	mean	N	O
exposure	NN	exposure	exposure	exposur	N	O
across	IN	across	across	across	N	O
studies	NNS	studies	study	studi	N	O
was	VBD	was	wa	wa	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
ATHENA	NNP	athena	athena	athena	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
maximum	JJ	maximum	maximum	maximum	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	NN	up	up	up	N	O
was	VBD	was	wa	wa	N	O
30	CD	30	30	30	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
premature	NN	premature	premature	prematur	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
11.8%	CD	11.8%	11.8%	11.8%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
dronedarone	NN	dronedarone	dronedarone	dronedaron	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
7.7%	CD	7.7%	7.7%	7.7%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reasons	NNS	reasons	reason	reason	N	O
for	IN	for	for	for	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
were	VBD	were	were	were	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
(	(	(	(	(	N	O
3.2	CD	3.2	3.2	3.2	N	O
versus	NN	versus	versus	versu	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
QT	NNP	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
versus	NN	versus	versus	versu	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBD	observed	observed	observ	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
5	CD	5	5	5	N	O
studies	NNS	studies	study	studi	N	O
were	VBD	were	were	were	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
displays	NNS	displays	display	display	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
more	RBR	more	more	more	N	O
common	JJ	common	common	common	N	O
with	IN	with	with	with	N	O
dronedarone	JJ	dronedarone	dronedarone	dronedaron	N	O
400	CD	400	400	400	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
than	IN	than	than	than	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
AF	NNP	af	af	af	N	O
or	CC	or	or	or	N	O
AFL	NNP	afl	afl	afl	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
presented	VBN	presented	presented	present	N	O
by	IN	by	by	by	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
and	CC	and	and	and	N	O
by	IN	by	by	by	N	O
decreasing	VBG	decreasing	decreasing	decreas	N	O
order	NN	order	order	order	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
and	CC	and	and	and	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
effects	NNS	effects	effect	effect	N	O
are	VBP	are	are	are	N	O
presented	VBN	presented	presented	present	N	O
separately	RB	separately	separately	separ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Drug	NNP	drug	drug	drug	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
Occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
Were	NNP	were	were	were	N	O
More	NNP	more	more	more	N	O
Frequent	NNP	frequent	frequent	frequent	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
Dronedarone	NNP	dronedarone	dronedarone	dronedaron	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O

(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
2875	CD	2875	2875	2875	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
3282	CD	3282	3282	3282	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

Diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction

6%	CD	6%	6%	6%	N	O
9%	CD	9%	9%	9%	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
3%	CD	3%	3%	3%	N	O
5%	CD	5%	5%	5%	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
3%	CD	3%	3%	3%	N	O
4%	CD	4%	4%	4%	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O

Dyspeptic	JJ	dyspeptic	dyspeptic	dyspept	N	B-AdverseReaction
signs	NNS	signs	sign	sign	N	I-AdverseReaction
and	CC	and	and	and	N	I-AdverseReaction
symptoms	NNS	symptoms	symptom	symptom	N	I-AdverseReaction
1%	CD	1%	1%	1%	N	O
2%	CD	2%	2%	2%	N	O

General	NNP	general	general	gener	N	O

Asthenic	JJ	asthenic	asthenic	asthen	N	B-AdverseReaction
conditions	NNS	conditions	condition	condit	N	I-AdverseReaction
5%	CD	5%	5%	5%	N	O
7%	CD	7%	7%	7%	N	O

Cardiac	NN	cardiac	cardiac	cardiac	N	O

Bradycardia	NNP	bradycardia	bradycardia	bradycardia	Y	B-AdverseReaction
1%	CD	1%	1%	1%	N	O
3%	CD	3%	3%	3%	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O

Including	VBG	including	including	includ	N	O
rashes	NNS	rashes	rash	rash	N	B-AdverseReaction
(	(	(	(	(	N	O
generalized	VBN	generalized	generalized	gener	N	I-AdverseReaction
,	,	,	,	,	N	O
macular	JJ	macular	macular	macular	N	I-AdverseReaction
,	,	,	,	,	N	O
maculo	JJ	maculo	maculo	maculo	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
,	,	,	,	,	N	O
erythematous	JJ	erythematous	erythematous	erythemat	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
eczema	NN	eczema	eczema	eczema	Y	B-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
allergic	VBD	allergic	allergic	allerg	N	I-AdverseReaction
3%	CD	3%	3%	3%	N	O
5%	CD	5%	5%	5%	N	O

Photosensitivity	NNP	photosensitivity	photosensitivity	photosensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
incidence	NN	incidence	incidence	incid	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

following	VBG	following	following	follow	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
data	NNS	data	data	data	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
parameters	NNS	parameters	parameter	paramet	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
data	NNS	data	data	data	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
parameters	NNS	parameters	parameter	paramet	N	O
not	RB	not	not	not	N	O
necessarily	RB	necessarily	necessarily	necessarili	N	O
reported	VBN	reported	reported	report	N	O
as	IN	as	a	as	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O

Placebo	NNP	placebo	placebo	placebo	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
400	CD	400	400	400	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O

(	(	(	(	(	N	O

N	NNP	n	n	n	N	O
2875	CD	2875	2875	2875	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
3282	CD	3282	3282	3282	N	O
)	)	)	)	)	N	O

Early	JJ	early	early	earli	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
10%	CD	10%	10%	10%	N	O
21%	CD	21%	21%	21%	N	O
51%	CD	51%	51%	51%	N	O

(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
2237	CD	2237	2237	2237	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
2701	CD	2701	2701	2701	N	O
)	)	)	)	)	N	O

QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
prolonged	VBD	prolonged	prolonged	prolong	N	I-AdverseReaction
19%	CD	19%	19%	19%	N	O
28%	CD	28%	28%	28%	N	O

Assessment	NN	assessment	assessment	assess	N	O
of	IN	of	of	of	N	O
demographic	JJ	demographic	demographic	demograph	N	O
factors	NNS	factors	factor	factor	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
gender	NN	gender	gender	gender	N	O
or	CC	or	or	or	N	O
age	NN	age	age	age	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
suggest	VB	suggest	suggest	suggest	N	O
an	DT	an	an	an	N	O
excess	NN	excess	excess	excess	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
particular	JJ	particular	particular	particular	N	O
sub	NN	sub	sub	sub	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O

Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
an	DT	an	an	an	N	O
unknown	JJ	unknown	unknown	unknown	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Cardiac	NNS	cardiac	cardiac	cardiac	N	O
:	:	:	:	:	N	O
New	NNP	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Atrial	JJ	atrial	atrial	atrial	N	B-AdverseReaction
flutter	NN	flutter	flutter	flutter	N	I-AdverseReaction
with	IN	with	with	with	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
:	:	:	:	:	N	I-AdverseReaction
1	CD	1	1	1	N	I-AdverseReaction
atrioventricular	JJ	atrioventricular	atrioventricular	atrioventricular	N	I-AdverseReaction
conduction	NN	conduction	conduction	conduct	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
very	RB	very	very	veri	N	O
rarely	RB	rarely	rarely	rare	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	O
:	:	:	:	:	N	O
Liver	NNP	liver	liver	liver	N	B-AdverseReaction
Injury	NNP	injury	injury	injuri	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Respiratory	NN	respiratory	respiratory	respiratori	N	O
:	:	:	:	:	N	O
Interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
fibrosis	NN	fibrosis	fibrosis	fibrosi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Immune	NN	immune	immune	immun	N	O
:	:	:	:	:	N	O
Anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction

Vascular	NN	vascular	vascular	vascular	N	O
:	:	:	:	:	N	O
Vasculitis	NN	vasculitis	vasculitis	vascul	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
leukocytoclastic	JJ	leukocytoclastic	leukocytoclastic	leukocytoclast	N	B-AdverseReaction
vasculitis	NN	vasculitis	vasculitis	vascul	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
STROKE	NNP	stroke	stroke	stroke	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
HEART	NNP	heart	heart	heart	N	B-AdverseReaction
FAILURE	NNP	failure	failure	failur	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DECOMPENSATED	NNP	decompensated	decompensated	decompens	N	O
HEART	NNP	heart	heart	heart	N	O
FAILURE	NNP	failure	failure	failur	N	O
OR	NNP	or	or	or	N	O
PERMANENT	NNP	permanent	permanent	perman	N	O
ATRIAL	NNP	atrial	atrial	atrial	N	O
FIBRILLATION	NNP	fibrillation	fibrillation	fibril	Y	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
STROKE	NNP	stroke	stroke	stroke	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
HEART	NNP	heart	heart	heart	N	B-AdverseReaction
FAILURE	NNP	failure	failure	failur	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DECOMPENSATED	NNP	decompensated	decompensated	decompens	N	O
HEART	NNP	heart	heart	heart	N	O
FAILURE	NNP	failure	failure	failur	N	O
OR	NNP	or	or	or	N	O
PERMANENT	NNP	permanent	permanent	perman	N	O
ATRIAL	NNP	atrial	atrial	atrial	N	O
FIBRILLATION	NNP	fibrillation	fibrillation	fibril	Y	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
and	CC	and	and	and	N	O
recent	JJ	recent	recent	recent	N	O
decompensation	NN	decompensation	decompensation	decompens	N	O
requiring	VBG	requiring	requiring	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
;	:	;	;	;	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
doubles	VBZ	doubles	double	doubl	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
14.3	CD	14.3	14.3	14.3	N	O
)	)	)	)	)	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
with	IN	with	with	with	N	O
recent	JJ	recent	recent	recent	N	O
decompensation	NN	decompensation	decompensation	decompens	N	O
requiring	VBG	requiring	requiring	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n\n\n\n	NN	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
permanent	JJ	permanent	permanent	perman	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
,	,	,	,	,	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
doubles	VBZ	doubles	double	doubl	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
for	IN	for	for	for	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
14.4	CD	14.4	14.4	14.4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

MULTAQ	NNP	multaq	multaq	multaq	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
(	(	(	(	(	N	O
AF	NNP	af	af	af	N	O
)	)	)	)	)	N	O
who	WP	who	who	who	N	O
will	MD	will	will	will	N	O
not	RB	not	not	not	N	O
or	CC	or	or	or	N	O
cannot	RB	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
cardioverted	VBN	cardioverted	cardioverted	cardiovert	N	O
into	IN	into	into	into	N	O
normal	JJ	normal	normal	normal	N	O
sinus	NN	sinus	sinus	sinu	N	O
rhythm	NN	rhythm	rhythm	rhythm	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n\n\n\n	FW	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
INCREASED	NNP	increased	increased	increas	N	O
RISK	NNP	risk	risk	risk	N	B-Factor
OF	NNP	of	of	of	N	O
DEATH	NNP	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
STROKE	NNP	stroke	stroke	stroke	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
HEART	NNP	heart	heart	heart	N	B-AdverseReaction
FAILURE	NNP	failure	failure	failur	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
DECOMPENSATED	NNP	decompensated	decompensated	decompens	N	O
HEART	NNP	heart	heart	heart	N	O
FAILURE	NNP	failure	failure	failur	N	O
OR	NNP	or	or	or	N	O
PERMANENT	NNP	permanent	permanent	perman	N	O
ATRIAL	NNP	atrial	atrial	atrial	N	O
FIBRILLATION	NNP	fibrillation	fibrillation	fibril	Y	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
with	IN	with	with	with	N	O
recent	JJ	recent	recent	recent	N	O
decompensation	NN	decompensation	decompensation	decompens	N	O
requiring	VBG	requiring	requiring	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
or	CC	or	or	or	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
.	.	.	.	.	N	O

MULTAQ	NNP	multaq	multaq	multaq	N	O
doubles	VBZ	doubles	double	doubl	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
14.3	CD	14.3	14.3	14.3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

MULTAQ	NNP	multaq	multaq	multaq	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
(	(	(	(	(	N	O
AF	NNP	af	af	af	N	O
)	)	)	)	)	N	O
who	WP	who	who	who	N	O
will	MD	will	will	will	N	O
not	RB	not	not	not	N	O
or	CC	or	or	or	N	O
cannot	RB	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
cardioverted	VBN	cardioverted	cardioverted	cardiovert	N	O
into	IN	into	into	into	N	O
normal	JJ	normal	normal	normal	N	O
sinus	NN	sinus	sinus	sinu	N	O
rhythm	NN	rhythm	rhythm	rhythm	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
permanent	JJ	permanent	permanent	perman	N	O
AF	NNP	af	af	af	N	O
,	,	,	,	,	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
doubles	VBZ	doubles	double	doubl	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
for	IN	for	for	for	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
14.4	CD	14.4	14.4	14.4	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Determine	NNP	determine	determine	determin	N	O
cardiac	VBZ	cardiac	cardiac	cardiac	N	O
rhythm	NN	rhythm	rhythm	rhythm	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
once	RB	once	once	onc	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
AF	NNP	af	af	af	N	O
is	VBZ	is	is	is	N	O
detected	VBN	detected	detected	detect	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
or	CC	or	or	or	N	O
cardiovert	NN	cardiovert	cardiovert	cardiovert	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Ensure	NN	ensure	ensure	ensur	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
antithrombotic	JJ	antithrombotic	antithrombotic	antithrombot	N	O
therapy	NN	therapy	therapy	therapi	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
and	CC	and	and	and	N	O
throughout	IN	throughout	throughout	throughout	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
use	NN	use	use	use	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
:	:	:	:	:	N	O
if	IN	if	if	if	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
injury	NN	injury	injury	injuri	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

If	IN	if	if	if	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Maintain	NNP	maintain	maintain	maintain	N	O
potassium	NN	potassium	potassium	potassium	Y	O
and	CC	and	and	and	N	O
magnesium	NN	magnesium	magnesium	magnesium	Y	O
levels	NNS	levels	level	level	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
normal	JJ	normal	normal	normal	N	O
range	NN	range	range	rang	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
Impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
periodically	RB	periodically	periodically	period	N	O
(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Teratogen	NN	teratogen	teratogen	teratogen	N	B-AdverseReaction
:	:	:	:	:	N	O
Women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	NN	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
use	VB	use	use	use	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
while	IN	while	while	while	N	O
using	VBG	using	using	use	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O

Death	NN	death	death	death	Y	O
in	IN	in	in	in	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
IV	NNP	iv	iv	iv	N	O
or	CC	or	or	or	N	O
Decompensated	VBN	decompensated	decompensated	decompens	N	O
Heart	NNP	heart	heart	heart	N	O
Failure	NN	failure	failure	failur	N	O

MULTAQ	NNP	multaq	multaq	multaq	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
NYHA	NNP	nyha	nyha	nyha	N	O
Class	NNP	class	class	class	N	O
IV	NNP	iv	iv	iv	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
or	CC	or	or	or	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
with	IN	with	with	with	N	O
recent	JJ	recent	recent	recent	N	O
decompensation	NN	decompensation	decompensation	decompens	N	O
requiring	VBG	requiring	requiring	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
because	IN	because	because	becaus	N	O
it	PRP	it	it	it	N	O
doubles	VBZ	doubles	double	doubl	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	O
Death	NNP	death	death	death	Y	O
and	CC	and	and	and	N	O
Heart	NNP	heart	heart	heart	N	O
Failure	NNP	failure	failure	failur	N	O
in	IN	in	in	in	N	O
Permanent	NNP	permanent	permanent	perman	N	O
AF	NNP	af	af	af	N	O

MULTAQ	NNP	multaq	multaq	multaq	N	O
doubles	VBZ	doubles	double	doubl	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
cardiovascular	JJ	cardiovascular	cardiovascular	cardiovascular	N	B-AdverseReaction
death	NN	death	death	death	Y	I-AdverseReaction
(	(	(	(	(	N	O
largely	RB	largely	largely	larg	N	O
arrhythmic	JJ	arrhythmic	arrhythmic	arrhythm	N	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
permanent	JJ	permanent	permanent	perman	N	O
AF	NNP	af	af	af	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
dronedarone	NN	dronedarone	dronedarone	dronedaron	N	O
should	MD	should	should	should	N	O
undergo	VB	undergo	undergo	undergo	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
rhythm	NN	rhythm	rhythm	rhythm	N	O
no	DT	no	no	no	N	O
less	RBR	less	le	less	N	O
often	RB	often	often	often	N	O
than	IN	than	than	than	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

Cardiovert	JJ	cardiovert	cardiovert	cardiovert	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
in	IN	in	in	in	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
(	(	(	(	(	N	O
if	IN	if	if	if	N	O
clinically	RB	clinically	clinically	clinic	N	O
indicated	VBN	indicated	indicated	indic	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
.	.	.	.	.	N	O

MULTAQ	NNP	multaq	multaq	multaq	N	O
offers	VBZ	offers	offer	offer	N	O
no	DT	no	no	no	N	O
benefit	NN	benefit	benefit	benefit	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
in	IN	in	in	in	N	O
permanent	JJ	permanent	permanent	perman	N	O
AF	NNP	af	af	af	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Increased	VBD	increased	increased	increas	N	O
Risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
Stroke	NNP	stroke	stroke	stroke	Y	O
in	IN	in	in	in	N	O
Permanent	NNP	permanent	permanent	perman	N	O
AF	NNP	af	af	af	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
permanent	JJ	permanent	permanent	perman	N	O
atrial	JJ	atrial	atrial	atrial	N	O
fibrillation	NN	fibrillation	fibrillation	fibril	Y	O
,	,	,	,	,	N	O
dronedarone	NN	dronedarone	dronedarone	dronedaron	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
stroke	NN	stroke	stroke	stroke	Y	B-AdverseReaction
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
two	CD	two	two	two	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.4	CD	14.4	14.4	14.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

MULTAQ	NNP	multaq	multaq	multaq	N	O
should	MD	should	should	should	N	O
only	RB	only	only	onli	N	O
be	VB	be	be	be	N	O
initiated	VBN	initiated	initiated	initi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
sinus	JJ	sinus	sinus	sinu	N	O
rhythm	NN	rhythm	rhythm	rhythm	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
receiving	VBG	receiving	receiving	receiv	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
antithrombotic	JJ	antithrombotic	antithrombotic	antithrombot	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Drug	NNP	drug	drug	drug	N	O
interactions	NNS	interactions	interaction	interact	N	O
(	(	(	(	(	N	O
7.3	CD	7.3	7.3	7.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
New	NNP	new	new	new	N	O
Onset	NNP	onset	onset	onset	N	O
or	CC	or	or	or	N	O
Worsening	NNP	worsening	worsening	worsen	N	O
Heart	NNP	heart	heart	heart	N	O
Failure	NN	failure	failure	failur	N	O

New	NNP	new	new	new	N	B-AdverseReaction
onset	PRP	onset	onset	onset	N	I-AdverseReaction
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
heart	NN	heart	heart	heart	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
controlled	VBN	controlled	controlled	control	N	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
permanent	JJ	permanent	permanent	perman	N	O
AF	NNP	af	af	af	N	O
increased	VBD	increased	increased	increas	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
left	VBD	left	left	left	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
function	NN	function	function	function	N	O
and	CC	and	and	and	N	O
no	DT	no	no	no	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
symptomatic	JJ	symptomatic	symptomatic	symptomat	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
or	CC	or	or	or	N	O
left	VBD	left	left	left	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	O
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
consult	VB	consult	consult	consult	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
develop	VBP	develop	develop	develop	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
weight	JJ	weight	weight	weight	Y	O
gain	NN	gain	gain	gain	N	O
,	,	,	,	,	N	O
dependent	JJ	dependent	dependent	depend	N	O
edema	NN	edema	edema	edema	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
increasing	VBG	increasing	increasing	increas	N	O
shortness	NN	shortness	shortness	short	N	O
of	IN	of	of	of	N	O
breath	NN	breath	breath	breath	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
develops	VBZ	develops	develops	develop	N	O
or	CC	or	or	or	N	O
worsens	NNS	worsens	worsens	worsen	N	O
and	CC	and	and	and	N	O
requires	VBZ	requires	requires	requir	N	O
hospitalization	NN	hospitalization	hospitalization	hospit	Y	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Liver	NNP	liver	liver	liver	N	O
Injury	NNP	injury	injury	injuri	Y	O

Hepatocellular	JJ	hepatocellular	hepatocellular	hepatocellular	N	B-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
transplant	NN	transplant	transplant	transplant	Y	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
postmarketing	NN	postmarketing	postmarketing	postmarket	N	O
setting	NN	setting	setting	set	N	O
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
to	TO	to	to	to	N	O
report	VB	report	report	report	N	O
immediately	RB	immediately	immediately	immedi	N	O
symptoms	JJ	symptoms	symptom	symptom	N	O
suggesting	VBG	suggesting	suggesting	suggest	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
injury	NN	injury	injury	injuri	Y	O
(	(	(	(	(	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	O
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	O
,	,	,	,	,	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
malaise	NN	malaise	malaise	malais	Y	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	O
,	,	,	,	,	N	O
right	JJ	right	right	right	N	O
upper	NN	upper	upper	upper	N	O
quadrant	NN	quadrant	quadrant	quadrant	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
jaundice	NN	jaundice	jaundice	jaundic	Y	O
,	,	,	,	,	N	O
dark	JJ	dark	dark	dark	N	O
urine	NN	urine	urine	urin	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
itching	VBG	itching	itching	itch	Y	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
obtaining	VBG	obtaining	obtaining	obtain	N	O
periodic	JJ	periodic	periodic	period	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
serum	NN	serum	serum	serum	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
whether	IN	whether	whether	whether	N	O
routine	JJ	routine	routine	routin	N	O
periodic	JJ	periodic	periodic	period	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
serum	NN	serum	serum	serum	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
will	MD	will	will	will	N	O
prevent	VB	prevent	prevent	prevent	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
injury	NN	injury	injury	injuri	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
promptly	RB	promptly	promptly	promptli	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
and	CC	and	and	and	N	O
test	NN	test	test	test	N	O
serum	NN	serum	serum	serum	N	O
enzymes	NNS	enzymes	enzyme	enzym	N	O
,	,	,	,	,	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
alanine	JJ	alanine	alanine	alanin	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
alkaline	JJ	alkaline	alkaline	alkalin	N	O
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	O
,	,	,	,	,	N	O
as	RB	as	a	as	N	O
well	RB	well	well	well	N	O
as	IN	as	a	as	N	O
serum	NN	serum	serum	serum	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
establish	VB	establish	establish	establish	N	O
whether	IN	whether	whether	whether	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
is	VBZ	is	is	is	N	O
found	VBN	found	found	found	N	O
,	,	,	,	,	N	O
institute	JJ	institute	institute	institut	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
investigate	VB	investigate	investigate	investig	N	O
the	DT	the	the	the	N	O
probable	JJ	probable	probable	probabl	N	O
cause	NN	cause	cause	caus	N	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
restart	VB	restart	restart	restart	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
without	IN	without	without	without	N	O
another	DT	another	another	anoth	N	O
explanation	NN	explanation	explanation	explan	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
observed	JJ	observed	observed	observ	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Cases	NNS	cases	case	case	N	O

of	IN	of	of	of	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
and	CC	and	and	and	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
fibrosis	NN	fibrosis	fibrosis	fibrosi	Y	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
setting	NN	setting	setting	set	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Onset	NNP	onset	onset	onset	N	O
of	IN	of	of	of	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
or	CC	or	or	or	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
productive	JJ	productive	productive	product	N	O
cough	NN	cough	cough	cough	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
carefully	RB	carefully	carefully	care	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
clinically	RB	clinically	clinically	clinic	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
is	VBZ	is	is	is	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	O
and	CC	and	and	and	N	O
Hypomagnesemia	NNP	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
with	IN	with	with	with	N	O
Potassium	NNP	potassium	potassium	potassium	Y	O
-	:	-	-	-	N	O
Depleting	VBG	depleting	depleting	deplet	N	O
Diuretics	NNS	diuretics	diuretic	diuret	N	O

Hypokalemia	NNP	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
with	IN	with	with	with	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
potassium	NN	potassium	potassium	potassium	Y	O
-	:	-	-	-	N	O
depleting	NN	depleting	depleting	deplet	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
.	.	.	.	.	N	O

Potassium	NN	potassium	potassium	potassium	Y	O
levels	NNS	levels	level	level	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
normal	JJ	normal	normal	normal	N	O
range	NN	range	range	rang	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
and	CC	and	and	and	N	O
maintained	VBN	maintained	maintained	maintain	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
normal	JJ	normal	normal	normal	N	O
range	NN	range	range	rang	N	O
during	IN	during	during	dure	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
QT	NNP	qt	qt	qt	N	O
Interval	NNP	interval	interval	interv	N	O
Prolongation	NNP	prolongation	prolongation	prolong	N	O

Dronedarone	NNP	dronedarone	dronedarone	dronedaron	N	O
induces	VBZ	induces	induces	induc	N	O
a	DT	a	a	a	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
(	(	(	(	(	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
about	IN	about	about	about	N	O
10	CD	10	10	10	N	O
ms	NNS	ms	m	ms	Y	O
but	CC	but	but	but	N	O
much	JJ	much	much	much	N	O
greater	JJR	greater	greater	greater	N	O
effects	NNS	effects	effect	effect	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
)	)	)	)	)	N	O
QTc	NNP	qtc	qtc	qtc	Y	B-AdverseReaction
(	(	(	(	(	N	O
Bazett	NNP	bazett	bazett	bazett	N	O
)	)	)	)	)	N	O
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.2	CD	12.2	12.2	12.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.1	CD	14.1	14.1	14.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
the	DT	the	the	the	N	O
QTc	NNP	qtc	qtc	qtc	Y	O
Bazett	NNP	bazett	bazett	bazett	N	O
interval	NN	interval	interval	interv	N	O
is	VBZ	is	is	is	N	O
500	CD	500	500	500	N	O
ms	NN	ms	m	ms	Y	O
,	,	,	,	,	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Renal	JJ	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
and	CC	and	and	and	N	O
Failure	NN	failure	failure	failur	N	O

Marked	JJ	marked	marked	mark	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
,	,	,	,	,	N	O
pre	SYM	pre	pre	pre	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
azotemia	NN	azotemia	azotemia	azotemia	Y	I-AdverseReaction
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
often	RB	often	often	often	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
setting	NN	setting	setting	set	N	O
of	IN	of	of	of	N	O
heart	NN	heart	heart	heart	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
or	CC	or	or	or	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
most	JJS	most	most	most	N	O
cases	NNS	cases	case	case	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
effects	NNS	effects	effect	effect	N	O
appear	VBP	appear	appear	appear	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
reversible	JJ	reversible	reversible	revers	N	O
upon	JJ	upon	upon	upon	N	O
drug	NN	drug	drug	drug	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
and	CC	and	and	and	N	O
with	IN	with	with	with	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
medical	JJ	medical	medical	medic	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
periodically	RB	periodically	periodically	period	N	O
.	.	.	.	.	N	O

Small	JJ	small	small	small	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
(	(	(	(	(	N	O
about	IN	about	about	about	N	O
0.1	CD	0.1	0.1	0.1	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
)	)	)	)	)	N	O
following	VBG	following	following	follow	N	O
dronedarone	NN	dronedarone	dronedarone	dronedaron	N	O
treatment	NN	treatment	treatment	treatment	N	O
initiation	NN	initiation	initiation	initi	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
shown	VBN	shown	shown	shown	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
a	DT	a	a	a	N	O
result	NN	result	result	result	N	O
of	IN	of	of	of	N	O
inhibition	NN	inhibition	inhibition	inhibit	N	O
of	IN	of	of	of	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	O
's	POS	's	's	's	N	O
tubular	JJ	tubular	tubular	tubular	N	O
secretion	NN	secretion	secretion	secret	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
elevation	NN	elevation	elevation	elev	N	O
has	VBZ	has	ha	ha	N	O
a	DT	a	a	a	N	O
rapid	JJ	rapid	rapid	rapid	N	O
onset	NN	onset	onset	onset	N	O
,	,	,	,	,	N	O
reaches	VBZ	reaches	reach	reach	N	O
a	DT	a	a	a	N	O
plateau	NN	plateau	plateau	plateau	N	O
after	IN	after	after	after	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
and	CC	and	and	and	N	O
is	VBZ	is	is	is	N	O
reversible	JJ	reversible	reversible	revers	N	O
after	IN	after	after	after	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
Childbearing	NNP	childbearing	childbearing	childbear	N	O
Potential	NNP	potential	potential	potenti	N	O

Premenopausal	NNP	premenopausal	premenopausal	premenopaus	N	O
women	NNS	women	woman	women	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
not	RB	not	not	not	N	O
undergone	VB	undergone	undergone	undergon	N	O
a	DT	a	a	a	N	O
hysterectomy	NN	hysterectomy	hysterectomy	hysterectomi	Y	O
or	CC	or	or	or	N	O
oophorectomy	NN	oophorectomy	oophorectomy	oophorectomi	Y	O
must	MD	must	must	must	N	O
use	VB	use	use	use	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
while	IN	while	while	while	N	O
using	VBG	using	using	use	N	O
MULTAQ	NNP	multaq	multaq	multaq	N	O
.	.	.	.	.	N	O

Dronedarone	NN	dronedarone	dronedarone	dronedaron	N	O
caused	VBD	caused	caused	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
in	IN	in	in	in	N	O
animal	JJ	animal	animal	anim	N	B-Animal
studies	NNS	studies	study	studi	N	O
at	IN	at	at	at	N	O
doses	NNS	doses	dos	dose	N	O
equivalent	JJ	equivalent	equivalent	equival	N	O
to	TO	to	to	to	N	O
recommended	VB	recommended	recommended	recommend	N	O
human	JJ	human	human	human	N	O
doses	NNS	doses	dos	dose	N	O
.	.	.	.	.	N	O

Counsel	NNP	counsel	counsel	counsel	N	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	JJ	potential	potential	potenti	N	O
regarding	VBG	regarding	regarding	regard	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
contraceptive	JJ	contraceptive	contraceptive	contracept	N	O
choices	NNS	choices	choice	choic	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

